Antimicrobial stewardship: the need to cover all bases by Friedman, N. Deborah
  
 
 
 
Friedman, N. Deborah 2013, Antimicrobial stewardship: the need to cover all bases, Antibiotics, vol. 2, no. 3, 
pp. 400-418. 
 
DOI: 10.3390/antibiotics2030400 
 
 
 
 
 
 
 
This is the published version. 
 
©2013, The Authors 
 
Reproduced by Deakin University under the terms of the Creative Commons Attribution Licence 
 
 
 
 
 
 
 
 
 
 
 
Available from Deakin Research Online: 
 
http://hdl.handle.net/10536/DRO/DU:30059330 
 
 
 
 
Antibiotics 2013, 2, 400-418; doi:10.3390/antibiotics2030400 
 
antibiotics 
ISSN 2079-6382 
www.mdpi.com/journal/antibiotics 
Review 
Antimicrobial Stewardship: The Need to Cover All Bases 
N. Deborah Friedman 
1,2
 
1
 Barwon Health, Bellerine St, Geelong, VIC 3220, Australia;  
E-Mail: Deborahf@barwonhealth.org.au; Tel.: +1-61-4215-2033; Fax: +1-61-4215-2385 
2
 Deakin University, Geelong, VIC 3216, Australia 
Received: 4 June 2013; in revised form: 18 August 2013 / Accepted: 21 August 2013 /  
Published: 27 August 2013  
 
Abstract: Increasing antimicrobial resistance has necessitated an approach to guide the use 
of antibiotics. The necessity to guide antimicrobial use via stewardship has never been 
more urgent. The decline in anti-infective innovation and the failure of currently available 
antimicrobials to treat some serious infections forces clinicians to change those behaviors 
that drive antimicrobial resistance. The majority of antimicrobial stewardship (AMS) 
programs function in acute-care hospitals, however, hospitals are only one setting where 
antibiotics are prescribed. Antimicrobial use is also high in residential aged care facilities 
and in the community. Prescribing in aged care is influenced by the fact that elderly 
residents have lowered immunity, are susceptible to infection and are frequently colonized 
with multi-resistant organisms. While in the community, prescribers are faced with public 
misconceptions about the effectiveness of antibiotics for many upper respiratory tract 
illnesses. AMS programs in all of these locations must be sustainable over a long period of 
time in order to be effective. A future with effective antimicrobials to treat bacterial 
infection will depend on AMS covering all of these bases. This review discusses AMS in 
acute care hospitals, aged care and the community and emphasizes that AMS is critical to 
patient safety and relies on government, clinician and community engagement. 
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1. Introduction  
Antibiotic resistance is an important public health concern [1], which is emerging rapidly on a 
global scale [2–4]. This increase in antimicrobial resistance has necessitated an approach to guide the 
use of antibiotics [4]. This necessity has never been more urgent. The decline in anti-infective 
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innovation and the failure of currently available antimicrobials to treat some serious infections is 
forcing clinicians to change those behaviors that drive antimicrobial resistance [5,6]. 
Antibiotic development has been dwindling since the 1990s. Compared with 1983 to 1987 when  
16 new antimicrobials were developed, this number has steadily declined to a mere two new 
antimicrobials developed from 2008–2012 [7]. Furthermore, there are a limited number of new 
antimicrobial agents currently in development that have microbiological activity against  
multidrug-resistant gram-negatives [2–4]. 
According to the Infectious Diseases Society of America (IDSA), antimicrobial stewardship (AMS) 
includes not only limiting inappropriate use but also optimizing antimicrobial selection, dosing, route 
and duration of therapy to maximize clinical cure or prevention of infection while limiting unintended 
consequences, such as the emergence of resistance. The ultimate goal of antimicrobial stewardship is 
to improve patient care and health care outcomes [8]. AMS can and ought to be practiced in hospitals, 
long-term care facilities, and the community in order to effectively curb a public health crisis. 
2. Locations for AMS Programs 
2.1. Antimicrobial Stewardship in Hospitals  
Hospital-based AMS programs are based on education coupled with either a ―front-end‖  
(or primary) restriction of antimicrobial availability or a ―back-end‖ (or retrospective) review of  
broad-spectrum empirical therapy with advice regarding streamlining or discontinuing therapy, on the 
basis of culture and susceptibility testing results and clinical response [3,9]. Hospital-based AMS 
programs are typically staffed by an antimicrobial pharmacist who performs post-prescription ward 
rounds supported by an infectious diseases team [1]. 
There are several other partners that are critical in hospital-based AMS programs. Medical 
Microbiologists and the microbiology laboratory have an important and often leading role to play in 
AMS both inside and outside of working hours [10,11]. The microbiologist and laboratory staff 
frequently monitor blood cultures, dispense prescribing advice, and provide timely antibiotic 
susceptibility data to allow for rationalization of empiric prescribing [10]. In one study, hospitals that 
routinely reported susceptibility results for restricted antibiotics had significantly lower median total 
antibiotic use [10]. In addition, new organism detection techniques, such as rapid polymerase chain 
reaction and matrix-assisted laser desorption and ionization time-of-flight mass spectrometry allows 
microbiologists to also play a pivotal role in improving time to optimal therapy, and decreasing 
hospital length of stay and total costs [12,13]. Clinical pharmacists are also increasingly important 
partners to infectious diseases physicians in implementation of antimicrobial stewardship programs [14]. 
Antimicrobial pharmacists share responsibility for activities such as development of guidelines  
for antimicrobial use, education of physicians and other health care professionals, review of  
hospital antimicrobial orders with feedback to providers, administration of restrictive strategies, 
pharmacokinetic consultation, and research on program outcomes [15]. Hospital programs in the future 
should recruit other champions, such as nursing staff, to the cause of stewardship. Nursing staff also 
have the potential to make a large contribution to the management of antimicrobials within an  
in-patient setting as they have the most consistent presence as patient carers [16]. 
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In hospital-based AMS programs that utilize more primary antimicrobial restriction to antibiotic 
availability, restrictions are placed on the availability of certain antimicrobial agents. Examples of such 
restrictions include the need for preapproval before the administration of restricted agents, and the use 
of special antimicrobial request or prescribing forms. Such programs, when properly implemented can 
result in large reductions in the overall use of some antimicrobials, but they are also time-consuming, 
labor intensive, require clinician buy-in and rely on experienced infectious diseases clinicians for  
their effectiveness [2,17]. 
The labor intensity of hospital-based AMS coupled with the rapid turnover of junior medical staff in 
many teaching hospitals create further challenges to both clinician engagement and AMS program 
sustainability in the longer-term. Furthermore, it may be that the prescribing practices of junior 
medical staff are not primarily influenced by guidelines. It has been demonstrated that the influences 
on prescribing behavior of non-consultant hospital medical staff are largely informal [18]. Prescribing 
by non-consultant medical staff in hospitals is based primarily on the immediate influence of more 
senior colleagues, with only a very minor influence from prescribing guidelines [18]. 
Aside from prescribing habits, there are several other factors that influence hospital-based 
prescribing. Clinicians are faced on a daily basis with patients whose outcomes will be markedly 
improved if treated early with broad-spectrum antibiotics [19,20]. Many hospital-based AMS programs 
do not primarily restrict antibiotic availability because of ethical concerns about the consequences of 
restriction of supply for acutely ill patients. The ethical conflict lies between the individual patient’s 
right to receive the ―best‖ antibiotic and the need to decrease the future number of drug-resistant 
pathogens [21,22]. These concerns may be well founded and will remain given the increase in the use 
of immunosuppressive medications in patients residing in the community [23], and the well described 
increase in multi-resistant organisms in both hospitalized and community-based patients [3].  
Hospital size will also influence AMS. Smaller hospitals or community-based hospitals may  
face major challenges developing and implementing AMS [24]. Storey et al. have described the 
implementation of an AMS program on the medical-surgical service of a 100-bed community hospital 
employing a core strategy of post-prescriptive audit with intervention and feedback. Their program, 
which had limited resources, was effective at reducing by 22% the defined daily doses of 
antimicrobials per 100 admissions [25]. Limited resources in another community institution influenced 
the implementation of a pharmacist-led AMS service using a clinical pharmacist and infectious  
disease physicians with the assistance of pharmacy residents and students [26]. Aside from the need 
for ward-based AMS in smaller regional or community hospitals, elective surgery is undertaken and 
substantial opportunities exist in smaller hospitals to improve compliance with published surgical 
antibiotic prophylaxis recommendations [27]. 
Prescribing is also influenced by ease and practicality. Both ease and practicality dictate that  
third-generation cephalosporins administered once daily are preferred over narrower spectrum 
penicillins (which require multiple daily doses or continuous infusion) in order to facilitate patient 
discharge in hospital-in-the-home programs. Ceftriaxone is a broad-spectrum cephalosporin with 
pharmacokinetic and antimicrobial characteristics that make it a good candidate for outpatient 
parenteral therapy [28,29]. Although anti-staphylococcal penicillins are the treatment of choice,  
studies have found that ceftriaxone compares favorably with oxacillin in the treatment of  
Methicillin-Susceptible Staphylococcus aureus infections [30]. Third-generation cephalosporins are 
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however the driving force behind resistance in Gram-negative bacteria [31], and their restriction, while 
important in AMS programs, may result in reduced efficiency and higher costs to hospitals through 
increased length of inpatient stay in this setting. 
In hospitals, constraints over the rapidity of completing patient assessment and care in emergency 
departments may also result in prescribing of broad-spectrum antimicrobials. The introduction of a  
4-hour rule into tertiary hospital emergency departments necessitates efficient completion of patient 
assessment and treatment. This 4-hour rule resulted in fewer deaths and a significant fall in mortality 
for patients admitted through those emergency departments [32,33]. However, prescribing therapy for 
a variety of possible pathogens (without microbiological results) may negatively impact prescribing 
habits. More rapid point of care testing is needed in order to either inform or reduce antibiotic 
prescribing in this setting.  
Supporting hospital-based AMS is expensive and given that many antimicrobials which stewardship 
seeks to restrict are now off patent and inexpensive, there are no major cost-savings of restriction  
that will offset the costs of an AMS program [34–36]. However, it has been demonstrated that 
antibiotic-resistant infections (ARIs) are extremely costly [7,37]. Roberts et al. found that the medical 
costs attributable to ARI ranged from $18,588 to $29,069 per patient with an excess duration of 
hospital stay of 6.4–12.7 days, and an attributable mortality of 6.5% [37]. These substantial costs of 
ARI strongly argue for the potential economic benefits of resistance prevention programs. 
2.2. Antimicrobial Stewardship in Long-Term Care Facilities  
However, hospitals are only one location where antibiotics are used. Antimicrobial use is also high 
in residential aged care facilities where 2%–5% of people over the age of 65 years reside [38,39]. With 
the anticipation of a doubling in the number of adults older than 65 years by 2050, there will be an 
increasing need for beds in long-term care facilities (LTCFs) [40]. AMS must extend into post-acute 
and aged care facilities in order to have an impact.  
The elderly are more susceptible to infection due to transmission of infection within their residential 
environment, and primary and secondary immune dysfunction [41,42]. In addition, residents in LTCFs 
are frequently colonized with multi-resistant organisms (MROs) [43]. It is these infections that are the 
cause of death in many patients with any form of end-stage illness [44]. In addition, in non-acute 
facilities, withholding antibiotics may result in an increase in mortality rates. For example, among 
patients in an extended care facility, withholding therapy during febrile episodes was associated with 
significantly higher mortality rates when compared with patients who received antibiotics (59% vs. 
9%) [21,45]. This type of evidence forms a compelling basis for prescribing of antibiotics in aged care.  
However, despite international guidelines suggesting the implementation of AMS in long-term care 
setting [46], well-delineated AMS strategies that are practical for this setting remain to be implemented 
on a large scale. In view of the differences in healthcare models and resources in aged care, AMS 
programs that function in the acute care hospital setting cannot be readily applied to the long-term care 
setting. It is thought that education and antimicrobial prescribing protocols in the aged care setting may 
help reduce unnecessary antimicrobial use [47]. 
Nicolle and others found that antimicrobials were the most commonly prescribed systemic drugs in 
long term care facilities and that up to three-quarters of antibiotic prescriptions for residents were 
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inappropriate over a decade ago [48]. Since then, evidence has been mounting on both the importance 
and effectiveness of educational interventions and antimicrobial stewardship in LTCFs.  
It is known that antimicrobial prescribing in residential aged care is often not based on culture-
proven infections, but is rather undertaken to manage reported symptoms, and most antimicrobial 
courses are initiated by telephone orders [49]. Recent studies reveal that antibiotics are prescribed for 
65% of residents over seven months, and that such prescribing is inappropriate in 20%–80% of  
cases [50,51]. Research has shown that reducing antibiotic use causes a reduction in MDR Gram-
negative bacteria and antimicrobial stewardship (including in LTCFs) is effective at reducing days of 
antibiotic therapy [52–54]. 
Jump and others have described their AMS program in a LTCF affiliated with a large urban 
Veterans Affairs (VA) medical center [55]. Their AMS team constituted an infectious diseases 
physician and a nurse practitioner who attended the facility weekly to deliver subspecialty expertise 
and were otherwise available for telephone consultation. Analysis revealed that 95% of their 
recommendations were followed, and that total antimicrobial use was reduced by 30%. After  
18 months of AMS, they found statistically significant reductions in the use of both oral and 
intravenous antibiotics, including impressive reductions in fluoroquinolones, anti-pseudomonal 
cephalosporins and beta-lactam-beta-lactamase inhibitor combinations [43]. During this period, there 
was also a reduction in positive Clostridium difficile tests. In contrast, the authors do describe an 
increase in the use of ceftriaxone and carbapenems. In terms of the cost of this type of AMS service, it 
can be difficult to calculate as many teams who provide such services are full-time employees of 
affiliated institutions [55]. 
The widespread and inappropriate use of antimicrobials in the LTCFs is partly due to difficulties in 
clinically assessing elderly patients [56,57]. Other contributing factors include the absence of  
on-site microbiology laboratory and pharmacy services [58]. In addition, AMS can be difficult to 
enforce in aged care facilities because of multiple off-site service providers, in an environment where 
institutional antimicrobial prescribing protocols are lacking [59], and often a desire on the part of 
prescribers to treat residents before they become seriously unwell [56]. Stuart et al. studied the 
prevalence of antimicrobial organisms in aged care facilities and found that in the 15 months before 
the study commenced, residents received antibiotics for 445 episodes, 44% of which did not fulfill the 
McGeer criteria for bacterial infection [56,60]. They also found that 10 of 12 residents colonized with 
extended-spectrum β-lactamase (ESBL) producing organisms had received antibiotics within the 
previous 6 months.  
2.3. Antimicrobial Stewardship in the Community 
Antimicrobial use in the community cannot be overlooked. Antibiotics are one of the most 
commonly prescribed drug classes worldwide, with considerable variation in outpatient antibiotic use 
between countries [61]. AMS in the community involves increasing public awareness, collection of 
antibiotic consumption and antimicrobial resistance data, and antibiotic conservation. Effective 
community-wide stewardship requires systems to be in place to monitor both antibiotic consumption 
and the appropriateness of prescriptions. However, in the absence of computerized prescribing, 
assessment of the quality of prescribing is more difficult to audit than consumption [62]. 
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In Europe, the European Surveillance of Antibiotic consumption (ESAC) collects comprehensive 
data about antibiotic consumption, which allows benchmarking, and is complemented by longitudinal 
and compositional data analyses [63]. Data from 1997 through 2009 revealed a significant increase in 
total outpatient antibiotic use. They also found that the relative use of penicillins and quinolones 
significantly increased over time compared to sulphonamides and trimethoprim, and that there was 
significant seasonal variation, which decreased over time. Of the countries involved in ESAC, Greece 
had the highest antibiotic consumption, and Romania had the lowest [63]. 
Viral respiratory tract infections drive antibiotic overprescribing in the outpatient setting, and this 
overprescribing is also influenced by patient demand and expectations [64,65]. In keeping with this 
phenomenon of patient demand, IDSA’s call to action for the medical community in 2008, asked us to 
educate our patients [7]. Public misconceptions about the effectiveness of antibiotics are common. In a 
survey in the Netherlands, 47% of responders believed that antibiotics are effective against viral 
infections [66]. These beliefs need to be taken into account in developing AMS programs in the 
community. McCraig recognized in 2002 that educating parents about appropriate antimicrobial use is 
the single most important factor in reducing unnecessary antimicrobial use [67]. 
It has been shown that prescribing in the community can also be influenced by the doctor’s 
perception of parental expectations. A survey was conducted of 306 parents of children 2–10 years of 
age with the presenting complaints of ear pain, throat pain, cough, or congestion. The researchers 
found that physicians’ perceptions of parental expectations for antimicrobials were the only significant 
predictor of prescribing antimicrobials for conditions of presumed viral etiology. When physicians 
thought a parent wanted an antimicrobial, they prescribed them 62% of the time versus 7% of the time 
when they did not think the parent wanted antimicrobials for their child [68]. 
Community-wide AMS programs require governments to invest heavily in education for both 
prescribers and the ―worried-well‖ in order to be effective. Advertising campaigns using all types of 
media forums have targeted raising awareness about the use of antibiotics. This has been exemplified 
well in Europe by national antibiotic awareness campaigns from the European Centre for Disease 
Prevention and Control (ECDC). Currently national campaigns take place in 29 European countries [69]. 
Slogans such as; ―Unfortunately no amount of antibiotics will get rid of your cold‖ and, ―Remember, 
antibiotics will not help your defenses against a cold‖ delivered the message about antibiotics to the 
public [69]. The ECDC also provides a toolkit for engaging in social media activities to promote 
prudent antibiotic use [70]. 
National campaigns are also underway in The United States of America, Canada and Australia. The 
United States Centers for Disease Control and Prevention’s campaign is entitled ―Get Smart: Know 
when antibiotics work‖ [71]. The Canadian antibiotic awareness campaign and Australia’s NPS 
Medicinewise programs target both patients and prescribers [72,73]. Australia’s campaign engaged 
social media encouraging the public to join the fight against antibiotic resistance by becoming a 
―resistance fighter‖ [73]. 
In the 1990s, one of the first national campaigns to reduce antibiotic prescribing resulted in a 
decrease in antibiotic use and penicillin-resistant Streptococcus pneumoniae in Iceland [74]. Since that 
time, there have been many other public campaigns, with a gradual increase in published data about 
their impact. Good evidence correlating a national campaign to a reduction in antibiotic use has come 
from Belgium. 
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Strong interdisciplinary leadership can be an important asset in developing national campaigns to 
target antimicrobial resistance. In Belgium, the Belgian Antibiotic Policy Coordination Committee 
(BAPCOC) established working groups composed of microbiologists, infectious diseases’ and 
infection control specialists, epidemiologists, general practitioners (GPs), pharmacists, nurses, 
veterinarians, basic researchers, public health experts and health economists. Using their combined 
expertise, multimedia campaigns were developed to promote the prudent use of antibiotics in the 
community, and surveillance programs on antibiotic use and resistance were established [75]. Their 
mass media campaigns were associated with a 36% reduction in antibiotic prescriptions between 
1999–2000 and 2006–2007 [75]. In addition, over a 5-year period, the Belgian campaign was able to 
show a substantial reduction in macrolide resistance in Streptococcus pyogenes.  
There is now increasing evidence that community-based AMS of a variety of agents can result in 
improvements in antimicrobial resistance. Gottesman et al. evaluated the impact of quinolone 
restriction on the antimicrobial resistance of E. coli urine isolates in a community setting [76]. They 
assessed the proportion of quinolone-susceptible E. coli urine isolates in the periods before, during, 
and after implementation of a nationwide restriction on ciprofloxacin use. The restriction campaign 
resulted in a significant decrease in E. coli nonsusceptibility to quinolones, from a mean of 12% before 
the intervention period to a mean of 9% in the intervention period (odds ratio, 1.35; p = 0.014). They 
were also able to demonstrate that the reversal in antimicrobial resistance may be short-lived as the 
improved susceptibility pattern reversed immediately when quinolone consumption rose [61]. 
France used to be known for the highest rates of antibiotic use and pneumococcal resistance in 
Europe. In 2001, French policy makers and public health authorities developed a coordinated and 
multifaceted strategy. It involved a yearly campaign targeting the public via mass media, conveying 
the message that ―Antibiotics Are Not Automatic‖ (especially for viral respiratory tract infections). In 
addition, they promoted both treatment guidelines and the use of the Streptococcal rapid antigen test. 
Primary care physicians were also targeted by one-on-one educational sessions (referred to as 
academic detailing). Using 90% complete national health insurance data for two winters before the 
campaign and five winters after the launch, they measured a decline of 26.5% in the number of 
antibiotic prescriptions. This exceeded their national target of a 25% reduction in prescribing. They 
also found that the greatest decrease in prescribing was observed in children and that the use of all 
antibiotic classes except fluoroquinolones decreased. The relative increase in fluoroquinolone use by 
12.8% was identified and the researchers hypothesized that this may be explained by the choice of 
antibiotic becoming less appropriate for certain treatment indications [77]. 
Aside from measuring antibiotic use and antimicrobial resistance, a multidisciplinary program in 
Sweden has been able to show that antibiotic use can be reduced without measurable negative 
consequences. Swedish Strategic Programme for the Rational Use of Antimicrobial Agents and 
Surveillance of Resistance (STRAMA) was initiated in Sweden in 1994 with a focus on inappropriate 
prescribing of antibiotics to children with respiratory tract infections and on the surveillance of 
resistance in pneumococci. Between 1993 and 1997 antibiotic prescribing was reduced by 22%, with 
the most pronounced reduction in children under six years of age. In addition, the national frequency 
of penicillin-non-susceptible pneumococci did not increase during the 1990s [78]. STRAMA was also 
able to show a 20% decrease in antibiotic use for outpatients, and a 52% reduction in antibiotic use in 
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children aged 5–14 with no increase in hospital admissions for acute mastoiditis, rhinosinusitis, and 
quinsy (peritonsillar abscess) [79]. 
National antimicrobial stewardship campaigns are expensive however. In France, developing and 
conducting their campaign cost 500 million EUR (653 million USD) over six years. In Belgium, the 
program cost 400,000 EUR (523,000 USD) per year, and in 2007 their annual budget was 7.8 million 
EUR (10.2 million USD). Without a more detailed cost-benefit analysis, this cost information is 
difficult to interpret. However, it is known that the reduction in antibiotic costs in France outweighed 
the cost of the public campaign to reduce prescribing [80]. 
An assessment of cost issues relevant to national AMS programs must take into account the amount 
of money spent by the pharmaceutical industry to promote antibiotics. In the United States in 1998, it 
was estimated that pharmaceutical companies spent about US $1.6 billion to promote antibiotics, an 
amount that vastly exceeds any budget allocated to antibiotic restriction campaigns [81]. 
Some of the more innovative campaigns aimed at reducing antibiotic use have used different 
outcome measures as their marker of success. The ideal outcome measure of antibiotic use is the 
incidence of Clostridium difficile infection (CDI). In Scotland, their program aimed to reduce the use 
of ―C. diffogenic agents‖, termed the ―4 C’s antibiotics‖. The antibiotics that they targeted for 
reduction were; cephalosporins, amoxicillin-clavulanic acid, clindamycin and ciprofloxacin, and they 
promoted the use of amoxicillin, co-trimoxazole, doxycycline, and gentamicin. Compared with 2008, 
there were 47,000 fewer antibiotic prescriptions, and the use of the 4 C’s decreased by 30%. There was 
also a 5% increase in the use of recommended antimicrobials over the study period. They were also 
able to demonstrate an impressive 42% reduction in the rate of CDI cases from 2006 to 2010 [82]. 
Antibiotic delay is a strategy that is used in the community and indeed should be encouraged. More 
use should be made of collecting samples for culture when it is thought that a prescription is justified. 
The majority of patients in general practice will not come to harm if a prescription is delayed overnight 
to allow time for initial culture, which may direct treatment [83]. 
Other strategies for better using existing antibiotics aim to optimize dosing, scheduling and 
duration. There is evidence of the influence of antibiotic duration on minimizing the development of 
antibiotic resistance. Drusano et al. describe instances when drug dose and/or schedule can be used to 
minimize the probability that mutants will take over the bacterial population [84]. In addition,  
Mouton et al. describe the concept of antibiotic conservation, which involves the optimization of 
dosing regimens by choosing the dose and schedule that results in the antimicrobial exposure that will 
achieve the microbiological and clinical outcome desired while simultaneously suppressing emergence 
of resistance [85]. The authors also suggest that both pharmacokinetic and pharmacodynamic 
relationships of older antibiotics need to be urgently established in order to inform the best ways to use 
old drugs [85]. 
3. Impacts of Antimicrobial Stewardship 
A reduction in total antibiotic use and expenditure are impacts of AMS, which have been well 
demonstrated [25,74,75,77,79,86–88]. AMS has also been shown to improve patient outcomes, and 
minimize antimicrobial resistance [74–76,89]. The Scottish Antimicrobial Prescribing Group has 
demonstrated not only a significant reduction in Clostridium difficile infection rates in Scotland, but 
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their program has also been successful at improving the clinical management of infections through 
quality improvement methodology [82]. Furthermore, AMS programs promote review of physician 
orders and therefore have been shown to allow for early detection and intervention of prescription 
errors [79]. Quality of care indicators, including patient safety are also improved secondary to AMS, 
and AMS can reduce hospital length of stay [88,90].  
4. The Role of Health Care Information Technology 
Traditionally, AMS programs relied on manual methods combined with clinical oversight and 
intervention. However, the advent of improved modern health care information technology has offered 
the opportunity to expand the breadth, depth, and efficiency of AMS programs. Point-of-care access to 
current medical information is easily available to the practitioner through the use of smartphones, 
iPads, and other personal digital assistants [91]. In addition, mobile health has enormous scope within 
AMS to both assist patients with antibiotic reminders, and to assist busy clinicians with antimicrobial 
information, clinical prescribing support and efficient collection of antimicrobial data [92,93].  
Expert computer clinical decision support systems have been a very promising information 
technology advance [94]. A seven-year study conducted in Salt Lake City, Utah, implemented  
computer-assisted decision support programs using local clinician-derived practice guidelines. They 
demonstrated that such decision support could improve antibiotic use, reduce associated costs, and 
stabilize the emergence of antibiotic-resistant pathogens in their institution [95]. A computerized 
antimicrobial approval system developed in Australia has also shown effectiveness in reducing the  
use of both 3rd and 4th generation cephalosporins, fluoroquinolones, glycopeptides and carbapenems 
with a favorable influence on local antibiograms [86,87]. Electronic clinical decision support via 
handheld devices has been shown to significantly reduce patient length of stay and antibiotic 
prescribing in a critical care unit, and to improve the appropriateness of antimicrobial selection for 
acute respiratory tract infections in a rural primary care setting [90,96].  
Recently, researchers in Minneapolis compared the appropriateness of antimicrobial courses 
ordered either with their computer decision support system or without such a system. They found that 
use of a decision support system was associated with significantly more appropriate antimicrobial 
prescribing [97]. In addition, a meta-analysis of studies found that clinicians with decision support 
were 1.6 times more likely to order recommended treatments than providers without such a system [98].  
However, this optimism must be balanced against potential pitfalls of electronic systems used in 
health care. Electronic health records are widely used in the United States, but many of these do not 
meet criteria for ―meaningful use‖ [99,100]. Only a small number of institutions have been able  
to demonstrate an improvement in safety, quality and efficiency as a result of such electronic  
systems [100]. In addition, an evaluation of a computerized decision support system (TheradoC) in 
Nebraska, which triggered prospective alerts regarding both the patient’s condition and the 
antimicrobial therapy, revealed that over 8,000 alerts were received over a 5-month period [101]. Only 
30% of these alerts were actionable, and the labor intensity of reviewing these alerts was substantial at 
approximately 5 hours per day. This type of system resulted in alert fatigue by staff [101]. Moreover, 
these types of systems need to move beyond the pre-prescription phase, and support the post 
prescription review process in order to be effective. 
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The dissemination of well-constructed electronic decision support systems has not been broad to 
date, likely due to issues of cost, the requirement for compatibility with existing electronic systems, 
and the fact that such systems cannot stand-alone and be effective. Such technology to assist 
prescribing must be part of a broader framework of AMS with an engaged AMS team in order to have 
an impact.  
5. Rapid Diagnostic Testing 
Rapid diagnostic testing (RDT), although not yet routine, is an important investment, which will 
likely contribute to a reduction in antibiotic use. RDT allows for rapid identification of group A 
streptococcus, human immunodeficiency virus (HIV), and bacteria such as methicillin-resistant 
Staphylococcus aureus (MRSA), Clostridium difficile, and extended spectrum beta-lactamase  
(ESBL)-producing organisms [102–108]. 
Rapid diagnostics are still predominantly performed in a laboratory. Such tests include; direct 
microscopy of specimens; antigen detection tests (such as enzyme immunoassay); molecular detection 
(nucleic acid probes and nucleic acid amplification); rapid biochemical tests (such as nitrite and 
leukocyte esterase performed on a urine dipstick); and serologic testing [102]. 
Rapid and accurate diagnosis of an infection should enhance patient outcome by enabling early 
initiation of appropriate therapy and implementation of relevant infection control measures, and 
reducing unnecessary antimicrobial treatment. In particular, molecular tests such as multiplex-PCR or 
a DNA-based microarray platform for detection of organisms causing sepsis have been developed  
and hold promise for rapid diagnosis of bacterial sepsis [102,104]. Despite the rapid progress of  
RDT technologies, these diagnostic modalities have not yet made many inroads toward replacing 
standard identification tests in medical microbiology laboratories. The unavailability of certain rapid 
tests is typically blamed on prohibitive costs and their doubtful cost-effectiveness. In addition, 
molecular-based RDTs have relatively lower sensitivities or positive predictive values compared with 
traditional methodologies for investigation or diagnosis of infections [102]. 
Clinicians can also utilize serum markers in order to decide whether antibiotics ought to be 
prescribed in a given patient. C-Reactive protein (CRP) is an acute-phase reactant, and CRP level 
measurements are frequently used to aid in the diagnosis of bacterial infections [109]. In addition, 
procalcitonin (PCT) is a hormone that has emerged as a promising marker for the diagnosis of bacterial 
infections and may be used to support clinical decision making for the initiation and discontinuation of 
antibiotic therapy [110,111]. It has been shown that PCT level is more sensitive and specific than the 
CRP level for differentiating bacterial from either viral or non-infective causes of inflammation [109]. 
Studies have demonstrated that higher levels of PCT are found in severe bacterial infections than in 
viral infections and nonspecific inflammatory diseases [112]. Studies in patients with acute respiratory 
infections have shown that measuring PCT is effective in reducing antibiotic exposure and that  
PCT guidance was not associated with increased mortality or treatment failure in any clinical  
setting [110]. In addition, randomized controlled trials have demonstrated the feasibility of using PCT 
in settings ranging from primary care to emergency departments, hospital wards and intensive care 
units [113–116]. Further validation of the use of PCT in all age groups and in patients with a variety of 
comorbidities such as immune compromise will be informative for clinicians. 
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6. Conclusions 
Preventing, reducing, and controlling the emergence of antimicrobial-resistant organisms is a major 
public health challenge that requires the participation of the entire medical community and public 
health agencies [18]. AMS initiatives should focus on the strategy of optimizing the use of currently 
available antimicrobials by using pharmacokinetic and pharmacodynamic principles such as extending 
time above the minimum inhibitory concentration in order to reduce antimicrobial resistance. It is 
however sobering to acknowledge that AMS in any setting, and the use of mobile health and RDTs 
may not be feasible for some time in resource-poor settings where MROs continue to evolve. AMS is 
critical to patient safety and relies on clinician and community engagement, and moving forward must 
routinely cover all bases. This requires government backing and strategies such as rapid diagnostics at 
the point of care and ongoing use of media forums to influence public opinion.  
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